Abstract:Importance Treatment of erythema and flushing in rosacea is challenging. Calcitonin gene-related peptide (CGRP) has been associated with the pathogenesis of rosacea, raising the possibility that inhibition of the CGRP pathway might improve certain features of the disease. Objective To examine the effectiveness, tolerability, and safety of erenumab, an anti–CGRP-receptor monoclonal antibody, for the treatment of rosacea-associated erythema and flushing. Design, Setting, and Participants This single-center, open-label, single-group, nonrandomized controlled trial was conducted between June 9, 2020, and May 11, 2021. Eligible participants included adults with rosacea with at least 15 days of either moderate to severe erythema and/or moderate to extreme flushing. No concomitant rosacea treatment was allowed throughout the study period. Visits took place at the Danish Headache Center, Copenhagen University Hospital, Rigshospitalet in Copenhagen, Denmark. Participants received 140 mg of erenumab subcutaneously every 4 weeks for 12 weeks. A safety follow-up visit was performed at week 20. Data analysis occurred from January 2023 to January 2024. Intervention 140 mg of erenumab every 4 weeks for 12 weeks. Main Outcomes and Measures The primary outcome was mean change in the number of days with moderate to extreme flushing during weeks 9 through 12, compared with the 4-week run-in period (baseline). The mean change in number of days with moderate to severe erythema was a secondary outcome. Adverse events were recorded for participants who received at least 1 dose of erenumab. Differences in means were calculated with a paired t test. Results A total of 30 participants (mean [SD] age, 38.8 [13.1] years; 23 female [77%]; 7 male [23%]) were included, of whom 27 completed the 12-week study. The mean (SD) number of days with moderate to extreme flushing was reduced by −6.9 days (95% CI, −10.4 to −3.4 days; P &lt; .001) from 23.6 (5.8) days at baseline. The mean (SD) number of days with moderate to severe erythema was reduced by −8.1 days (95% CI, −12.5 to −3.7 days; P &lt; .001) from 15.2 (9.1) days at baseline. Adverse events included transient mild to moderate constipation (10 participants [33%]), transient worsening of flushing (4 participants [13%]), bloating (3 participants [10%]), and upper respiratory tract infections (3 participants [10%]), consistent with previous data. One participant discontinued the study due to a serious adverse event (hospital admission due to gallstones deemed unrelated to the study), and 2 participants withdrew consent due to lack of time. Conclusions and Relevance These findings suggest that erenumab might be effective in reducing rosacea-associated flushing and chronic erythema (participants generally tolerated the treatment well, which was consistent with previous data), and that CGRP-receptor inhibition holds potential in the treatment of erythema and flushing associated with rosacea. Larger randomized clinical trials are needed to confirm this finding. Trial Registration ClinicalTrials.gov Identifier: NCT04419259

Elevated plasma levels of calcitonin gene‐related peptide in individuals with rosacea: A cross‐sectional case–control study

Erenumab for Treatment of Persistent Erythema and Flushing in Rosacea

Reduced plasma calcitonin gene-related peptide level identified in cluster headache: A prospective and controlled study

Calcitonin Gene-Related Peptide Inhibition and Development of Acne and Rosacea

High-sensitive sensory neurons exacerbate rosacea-like dermatitis in mice by activating γδ T cells directly

Identification of novel candidate genes in rosacea by bioinformatic methods

Bisphenol-A and pentachlorophenol sodium levels in patients with rosacea

Rosacea and gastrointestinal diseases: A case-control study in the All of Us database

Serum calcitonin gene-related peptide in patients with persistent post-concussion symptoms, including headache: a cohort study

Elevated Specific Pro-Inflammatory Cytokines in Peripheral Circulation Indicate an Increased Risk of Anxiety and Depression in Rosacea

Elucidating the Ability of CGRP to Modulate Microvascular Events in Mouse Skin

Keratinocyte-Immune Cell Crosstalk in a STAT1-Mediated Pathway: Novel Insights Into Rosacea Pathogenesis

EGCG identified as an autophagy inducer for rosacea therapy

Characteristics of Gut Microbiota in Rosacea Patients—A Cross-Sectional, Controlled Pilot Study

Clinical characteristics of the well‐defined upper eyelid vascular network pattern in patients with rosacea

A comprehensive epidemiological study of rosacea in Germany

Single-cell transcriptomics reveals aberrant skin-resident cell populations and identifies fibroblasts as a determinant in rosacea

Calcitonin Gene-Related Peptide Level in Cystic Fibrosis Patients

THE ROLE OF ENDOGENOUS NEUROPEPTIDES IN THE PATHOGENESIS AND CLINICAL MANIFESTATIONS OF ROSACEA-TIDES IN WOMEN

Serum levels of hypersensitive-C-reactive protein in moderate and severe acne

Exploring the efficacy of laser speckle contrast imaging in the stratified diagnosis of rosacea: a quantitative analysis of facial blood flow dynamics across varied regions